Core Points - The company did not distribute cash dividends or issue bonus shares during the reporting period [3] - The company’s controlling shareholder and actual controller did not change during the reporting period [5] - The company’s subsidiary Tianyuan Pharmaceutical won the bid for the centralized procurement of traditional Chinese medicine in Guangdong [5] - The company received various drug registration certificates and approvals for its products in 2025 [5][6] - The company completed the redemption of its convertible bonds in August 2025 [6] - The company’s subsidiary Haichang Pharmaceutical obtained market access for several raw materials in South Korea and India [6] Financial Data and Indicators - The report indicates that all board members attended the meeting to review the report [2] - The company’s half-year report was disclosed on August 26, 2025, on designated platforms [8] - The company confirmed the accuracy and completeness of the information disclosed in the report [8]

Group 1 - The company participated in a centralized procurement program in Xinjiang, aiming to select its gadobutrol injection and gadopentetate dimeglumine injection [1] - The proposed price for gadopentetate dimeglumine injection (15ml:7.04g) is 80.26 yuan per unit, while gadobutrol injection (15ml:7.935g) is priced at 185.69 yuan per unit [1] - For the year 2024, the sales revenue from gadopentetate dimeglumine injection is projected to be 236 million yuan, accounting for 24.01% of the company's total revenue for the period [1]